Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 323

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 323
---
 of such litigation or proceedings more
effectively than we can because of their substantially greater financial resources. The effects of patent litigation or other proceedings
could therefore have a material adverse effect on our ability to compete in the marketplace.

Issued patents covering our drug candidates, compositions or
uses could be found invalid or unenforceable if challenged in a patent office or court.

Even if our patents or our past, current or future
collaboration partners’ or licensors’ patents do successfully issue and even if such patents cover our technologies, drug
candidates, compositions or methods of use, third parties may initiate interference, re-examination, post-grant review, inter partes review
(“IPR”) or derivation actions in the USPTO; may initiate third party oppositions in the EPO; or may initiate similar actions
challenging the validity, enforceability, scope or term of such patents in other patent administrative or court proceedings worldwide,
which may result in patent claims being narrowed or invalidated. Such proceedings could result in revocation or amendment of our patents
in such a way that they no longer cover competitive technologies, drug candidates, compositions or methods of use. Further, if we initiate
legal proceedings against a third party to enforce a patent covering our technologies, drug candidates, compositions or uses, the defendant
could counterclaim that our relevant patent is invalid or unenforceable. In patent litigation in the United States, certain European and
other countries worldwide, it is commonplace for defendants to make counterclaims alleging invalidity and unenforceability in the same
proceeding, or to commence parallel defensive proceedings such as patent nullity actions to challenge validity and enforceability of asserted
patent claims. Further, in the United States, a third party, including a licensee of one of our past, current, or future collaboration
partners’ patents, may initiate legal proceedings against us in which the third party challenges the validity, enforceability, or
scope of our patent(s).

In administrative and court actions, grounds for
a patent validity challenge may include alleged failures to meet any of several statutory requirements, including novelty, nonobviousness
(or inventive step), clarity, adequate written description and enablement of the claimed invention. Grounds for unenforceability assertions
include allegations that someone associated with the filing or prosecution of the patent withheld material information from the Examiner
during prosecution in the USPTO or made a misleading statement during prosecution in the USPTO, the EPO or elsewhere. Third parties also